KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $1.4 million.

  • AbCellera Biologics' Other Non-Current Liabilities fell 6879.08% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 6879.08%. This contributed to the annual value of $1.5 million for FY2024, which is 7512.7% down from last year.
  • Per AbCellera Biologics' latest filing, its Other Non-Current Liabilities stood at $1.4 million for Q3 2025, which was down 6879.08% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Other Non-Current Liabilities ranged from a high of $44.9 million in Q3 2021 and a low of $1.4 million during Q3 2025
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $6.3 million (2024), whereas its average is $13.3 million.
  • As far as peak fluctuations go, AbCellera Biologics' Other Non-Current Liabilities skyrocketed by 29228.25% in 2021, and later crashed by 7909.58% in 2023.
  • AbCellera Biologics' Other Non-Current Liabilities (Quarter) stood at $35.9 million in 2021, then crashed by 55.26% to $16.1 million in 2022, then crashed by 63.21% to $5.9 million in 2023, then plummeted by 75.13% to $1.5 million in 2024, then decreased by 5.65% to $1.4 million in 2025.
  • Its Other Non-Current Liabilities stands at $1.4 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.6 million for Q1 2025.